Boston Scientific Corporation
BSXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Boston Scientific Corporation (BSX) is listed under Medical Devices. Valued at $66.22B, BSX is a large-cap name in its sector. The company operates in two segments, MedSurg and Cardiovascular.
Market Cap
$66.22B
Beta
0.57
P/E (TTM)
18.50
P/E (Fwd)
13.53
EPS (TTM)
$2.47
EPS (Fwd)
$3.38
ROE
15.3%
ROA
6.2%
Cash
$539.0M
Total Debt
$12.62B
Free CF
$2.45B
52W Change
-55.4%
Annual Financials
Cash vs Debt
Where BSX stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, BSX finished 16.44% below its 150-day moving average ($51.46) and 27.88% below its 200-day moving average ($59.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BSX overbought or oversold?
At the October 15, 2026 close, BSX's RSI(14) was 37.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $539.0M in cash, though total debt stands at $12.62B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $2.45B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 15.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $12.68B (2022) to $20.07B (2025), reflecting a 58% increase over the period.
With a beta below 0.7, Boston Scientific Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Boston Scientific Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Boston Scientific Corporation and its sector.